These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 9797415)

  • 61. Comparative activity of cefixime and cefaclor in an in vitro model simulating human pharmacokinetics.
    Nies BA
    Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):558-61. PubMed ID: 2504600
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Therapeutic options for cefotaxime in the management of bacterial infections.
    Raddatz JK; Ostergaard BE; Rotschafer JC
    Diagn Microbiol Infect Dis; 1995; 22(1-2):77-83. PubMed ID: 7587054
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of oral cefixime and intravenous ceftriaxone followed by oral amoxicillin in disseminated Lyme borreliosis.
    Oksi J; Nikoskelainen J; Viljanen MK
    Eur J Clin Microbiol Infect Dis; 1998 Oct; 17(10):715-9. PubMed ID: 9865985
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cefotaxime and desacetylcefotaxime antimicrobial interactions. The clinical relevance of enhanced activity: a review.
    Jones RN
    Diagn Microbiol Infect Dis; 1995; 22(1-2):19-33. PubMed ID: 7587039
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cefotaxime twice daily versus ceftriaxone once daily. A randomized controlled study in patients with serious infections.
    Simmons BP; Gelfand MS; Grogan J; Craft B
    Diagn Microbiol Infect Dis; 1995; 22(1-2):155-7. PubMed ID: 7587031
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Outpatient therapy with ceftriaxone and oral cefixime for selected febrile children with sickle cell disease.
    Williams LL; Wilimas JA; Harris SC; Day SW; Dancy RM; Wang WC
    J Pediatr Hematol Oncol; 1996 Aug; 18(3):257-61. PubMed ID: 8689337
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The pharmacokinetic and bactericidal characteristics of oral cefixime.
    Brittain DC; Scully BE; Hirose T; Neu HC
    Clin Pharmacol Ther; 1985 Nov; 38(5):590-4. PubMed ID: 4053491
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Safety and efficacy of cefixime in treatment of respiratory tract infections in Germany.
    Hausen T; Weidlich G; Schmitt J
    Infection; 1995; 23 Suppl 2():S65-9. PubMed ID: 8537134
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pharmacokinetic profile of cefixime in man.
    Faulkner RD; Yacobi A; Barone JS; Kaplan SA; Silber BM
    Pediatr Infect Dis J; 1987 Oct; 6(10):963-70. PubMed ID: 3696837
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The role of cefotaxime in the treatment of surgical infections.
    Wittmann DH
    Diagn Microbiol Infect Dis; 1995; 22(1-2):173-82. PubMed ID: 7587036
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Role of pharmacokinetics and pharmacodynamics in the design of dosage schedules for 12-h cefotaxime alone and in combination with other antibiotics.
    Nix DE; Schentag JJ
    Diagn Microbiol Infect Dis; 1995; 22(1-2):71-6. PubMed ID: 7587053
    [TBL] [Abstract][Full Text] [Related]  

  • 72. In vitro activity of two new oral cephalosporins, cefixime and cefdinir (CI 983), on human peripheral mononuclear and polymorphonuclear leukocyte functions.
    Fietta A; Merlini C; Gialdroni Grassi G
    Chemotherapy; 1994; 40(5):317-23. PubMed ID: 7956455
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Third-generation cephalosporins in the treatment of acute pneumococcal otitis media. An animal study.
    Rosenfeld RM; Doyle WJ; Swarts JD; Seroky J; Pinero BP
    Arch Otolaryngol Head Neck Surg; 1992 Jan; 118(1):49-52. PubMed ID: 1728277
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Sequential therapy with intravenous and oral cephalosporins.
    Janknegt R; van der Meer JW
    J Antimicrob Chemother; 1994 Jan; 33(1):169-77. PubMed ID: 8157558
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pneumococcal bacteremia during oral treatment with cefixime for otitis media.
    Ottolini MG; Ascher DP; Cieslak TJ; Modica-Lucero S
    Pediatr Infect Dis J; 1991 Jun; 10(6):467-8. PubMed ID: 1852543
    [No Abstract]   [Full Text] [Related]  

  • 76. An experimental study of cefixime in the treatment of Streptococcus pneumoniae otitis media.
    Magit AE; Dolitsky JN; Doyle WJ; Swarts JD; Seroky JT; Rosenfeld RM
    Int J Pediatr Otorhinolaryngol; 1994 Mar; 29(1):1-9. PubMed ID: 8169042
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cefixime.
    Long SS
    Pediatr Ann; 1993 Mar; 22(3):177-81, 185-6. PubMed ID: 8464649
    [No Abstract]   [Full Text] [Related]  

  • 78. Clinical pharmacology of cefixime in unweaned calves.
    Ziv G; Lavy E; Glickman A; Winkler M
    J Vet Pharmacol Ther; 1995 Apr; 18(2):94-100. PubMed ID: 7629935
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cefotaxime versus ceftriaxone for the treatment of nosocomial pneumonia. Results of a multicenter study.
    Shah PM; Stille W
    Diagn Microbiol Infect Dis; 1995; 22(1-2):171-2. PubMed ID: 7587035
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Retrospective analysis of the clinical and economic outcomes of twice-daily dosing of cefotaxime in a Canadian tertiary care institution.
    Tin LY; Pitre M; Conly JM
    Diagn Microbiol Infect Dis; 1995; 22(1-2):135-40. PubMed ID: 7587028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.